TD Cowen analyst Josh Jennings has maintained their bullish stance on JNJ stock, giving a Buy rating on March 11.
Josh Jennings has given his Buy rating due to a combination of factors including Johnson & Johnson’s strategic initiatives to enhance its orthopedic segment. The company is focusing on simplifying operations by reducing SKUs by 25% and optimizing its supply chain, which is expected to drive organic revenue growth to the higher end of the industry average.
Additionally, J&J is expanding its robotics and AI capabilities in key areas such as knees, hips, and trauma, which are anticipated to improve surgical precision and efficiency. By targeting high-growth segments like cementless knees and revision hips, and leveraging ASC-driven growth, the company is poised to capitalize on significant market opportunities. This strategic shift from being an implant-focused entity to a comprehensive procedural solutions provider underpins the positive outlook for J&J’s stock.
In another report released on March 11, RBC Capital also maintained a Buy rating on the stock with a $181.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com